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impactEye disorders rank high in the list of morbid conditions in all
societies. Their landscape is strikingly different, however, be-
tween developed countries and those that are still low in the
development ladder. As is typical of other organ systems,
infectious diseases tend to occupy a fat slice of the frequency
pie chart for eye disorders in underdeveloped countries. The
Kingdom of Saudi Arabia has made signiﬁcant strides in the
recent past in addressing public health priorities and this has
resulted in a changing pattern that is slowly conforming to that
typical of more developed countries where infectious diseases
are giving way to chronic diseases, ophthalmology being no
exception in this trend. While this is easily seen in the increas-
ing impact such common eye diseases as diabetic retinopathy,
this change in paradigm has also given more visibility to the
genetic eye disorders, among other genetic diseases, which, de-
spite their perceived rarity, are considerably more common in
Saudi Arabia compared to the world’s average because of
inbreeding and large family size. These two population charac-
teristics are of undoubted importance in boosting the fre-
quency of Mendelian diseases, autosomal recessive ones in
particular. It is important to note here that this is as much
an opportunity as it is a challenge. Many of the arguably most
notable breakthrough discoveries in ophthalmology genetics
can be traced to the successful utilization of gene mapping
strategies on Saudi patients, taking advantage of the unique
population characteristics described above. There is also
mounting interest in utilizing these characteristics to identify
risk loci/alleles for more complex eye disorders such as diabetic
retinopathy. Our research group has taken on the challenge to
study genetic eye disorders in the Kingdom supported by a
grant from King Abdulaziz City for Science and Technology
as part of the National Strategic Plan for Science and Technol-
ogy. The short time that lapsed between the establishment of1319-4534 ª 2010 King Saud University. All rights reserved. Peer-
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that describe novel genetic aspects pertaining to the eye speaks,
among other things, to the fertility of eye genetic research in
this country and the good return of this research investment.
No doubt, genetic disorders, at least in the Mendelian
genetics sense, tend to be more difﬁcult to treat compared to
infectious disorders but one must not forget that treatment is
only part of the management and all too often ophthalmolo-
gists, like other clinicians, overlook the tremendous potential
for prevention these disorders are amenable to particularly
when the molecular defect is identiﬁed. As an immediate trans-
lational beneﬁt of our research, genetic counseling is intricately
integrated and the number of families taking advantage of
preventative genetic services in the form of early prenatal
and preimplantation genetic diagnosis is rising very rapidly.
Importantly, cascade carrier testing of the extended family
members, while continues to be a challenge for cultural rea-
sons, is also on the rise and a national strategy to take this
to its full potential is urgently needed given the considerable re-
turn for the investment in this area. But our investment in pre-
vention, the importance of which cannot be overemphasized,
should not deter us from the pursuit of treatment. While some
genetic eye disorders are in fact long known to be treatable,
particularly the metabolic ones, I would like to emphasize here
the exciting new frontiers. Regenerative medicine using stem
cells and nano-scale technologies is looming in the horizon
and gene therapy has turned into reality in the very recent past
for some of the most hopeless eye disorders (Bainbridge et al.,
2008; Cideciyan et al., 2008; Maguire et al., 2008; Thomson
and Lotery, 2009; Viczian et al., 2009). In this regard, our
group is pleased to take this opportunity to announce the
launch of clinical gene therapy for MERTK-related retinal
degeneration in the very near future. The latter is in fact an-
other example of the global impact of research in genetic oph-
thalmology in Saudi Arabia. While MERTK-related retinal
dystrophy was long known for its excellent candidacy for gene
therapy given the successful application of this technology on
rats naturally deﬁcient for this protein, the lack of human pa-
tients was a major factor for why this was not the ﬁrst gene
therapy trial in human retina. Our ongoing molecular charac-
terization of retinal diseases in Saudi Arabia has identiﬁed,
however, several families with multiple affected children with
110 EditorialMERTK mutations by harnessing the power of autozygosity
mapping which we have used and continue to use successfully
in this and other research endeavors.
So what is next? It is imperative that local training in oph-
thalmology, widely reputed for its clinical excellence, integrate
research in its curriculum. Young ophthalmologists with back-
ground in research are badly needed to ﬁll in the huge gap that
currently exists between available biological resources and
qualiﬁed manpower in genetic ophthalmology research in Sau-
di Arabia. Basic scientists are eager to team up with such oph-
thalmologists to bring about fruitful collaborative research in
the true sense of the word. The mandate is signiﬁcant because
this research is not only going to deliver to local patients but
will transcend in its relevance to the global scientiﬁc commu-
nity that is eager to see the full utilization of the potential
our unique population has to offer.References
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